The Amin lab is focused upon drug discovery for metabolic related diseases with a focus upon neurodegeneration and liver fibrosis. We use computational chemistry methods for developing novel chemical therapeutics for diseases associated with fatty liver disease, NASH and Alzheimer's disease A major area of focus in the lab is related to developing novel therapeutics for fighting the progression of liver damage from nonalcoholic fatty liver disease (NAFLD) to Non-alcoholic steatotic hepatitis (NASH). We have developed novel compounds based upon in silico design. areas of interest include: Nuclear receptors; including partial PPAR gamma, PPAR delta agonist, LXR - PPAR-alpha agonist. FMO3 inhibitors: We are focused upon Trimethylamine oxide induces pathology and promotes alteration in spine density in Alzheimer's disease and diabetes type 2 patients. Spine density protection: In the signaling cascade involving reduced spine density in Alzheimer's disease and diabetes the activation and inhibition of cofilin activity. We currently developing novel tools to better understand the ying and yang interplay of Lim-kinase and Slingshot on spine density under inflammatory conditions in neurodegenerative models.